TR1801-ADC / Mitsubishi Tanabe, Open Innovation Partners - LARVOL DELTA

TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov) - P1 | N=15 | Suspended | Sponsor: Open Innovation Partners, Inc. | N=40 ➔ 15 | Trial completion date: Mar 2023 ➔ Dec 2023 | Active, not recruiting ➔ Suspended | Trial primary completion date: Mar 2023 ➔ Jul 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial suspension • Oncology • Solid Tumor • MET

TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Tanabe Research Laboratories USA Inc | Active, not recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • MET

TR1801-ADC in Patients With Tumors That Express c-Met (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Tanabe Research Laboratories USA Inc; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Oncology • Solid Tumor • MET

A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. (PubMed, Clin Cancer Res) - "Together these results suggest the promise of agents such as TR1801-ADC as a novel approach to the treatment of pancreatic cancer."

Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • MET